Diaceutics Plc | DXRX | AIM

Diaceutics (LSE:DXRX) has spent the past year converting a long-promised strategy into harder financial numbers, and the AIM-quoted precision-medicine specialist appeared on a 27 August 2026 market screen against a backdrop of improving profitability. The Belfast-headquartered group sits at the intersection of pharmaceutical Marketing and diagnostic data, a niche that has taken time to monetise but that is now showing clearer signs of operating leverage. After years of heavy Investment in its platform, the story has shifted from potential to demonstrated returns.

What Diaceutics does

The company helps pharmaceutical firms improve the testing and diagnosis that determine whether patients are identified for targeted therapies. Its DXRX platform pulls together diagnostic laboratory data, clinical intelligence and real-world healthcare information, which drug makers use to find undiagnosed patients and smooth the path from test to treatment. Diaceutics (LSE:DXRX) says it works with 18 of the top 20 global pharma companies, and that its platform influenced diagnostic and treatment decisions for some 970,000 patients globally in 2025.

Results moving in the right direction

For the year to 31 December 2025, reported in May 2026, Revenue rose 20% to £38.4m, or 24% in constant currency. Annual Recurring Revenue climbed 19% to £20.0m, and adjusted EBITDA jumped 80% to £7.6m, lifting the Margin to 20% from 13%. Crucially the group returned to a profit before tax of £0.3m, against a £1.9m loss the prior year. The order book grew 56% to £38.9m, with £21.1m visible for the coming twelve months, and first-quarter 2026 trading was in line with expectations at 15% constant-currency growth.

Sector backdrop

The wider precision-medicine market has expanded as more approved therapies depend on a companion diagnostic to identify eligible patients. That structural trend is favourable for Diaceutics, whose pitch is that many suitable patients are never correctly tested and so never reach the right treatment. The company has broadened its ambition under a 'Precision for All' banner, targeting diagnostically driven therapies beyond the traditional precision-oncology core, and has added AI-enabled automation and electronic medical record integrations to its platform.

Balance sheet and risks

Cash ended the year at £7.3m, down from £12.7m, which the company attributed to back-end-weighted revenue and extended customer Credit terms — a reminder that working-capital timing matters for a Business scaling its enterprise deals. Risks include customer concentration, given reliance on a relatively small number of large pharma clients, and the lumpiness that can come with big contracts. As a smaller technology company, Diaceutics is also exposed to the pace of pharma marketing budgets, the timing of drug launches and the broader adoption of precision diagnostics.

What to watch

Potential catalysts include further enterprise-wide partnerships, continued growth in annual recurring revenue and conversion of the enlarged order book into cash. A second commercialisation Partnership signed late in 2025 points to an emerging platform revenue stream. The key question is whether Diaceutics can pair its revenue momentum with steadier cash generation. After years of investment, 2025 marked a return to profitability; investors are likely to watch whether 2026 confirms that the model has reached a durable inflection point.